A process is disclosed for producing an avirulent attenuated live virus vaccine for use in immunizing horses against equine viral arteritis and for simultaneously obviating the transmission of the disease from a vaccinated horse to a non-vaccinated horse. The invention also includes the product derived from practice of the process and typical examples of the efficacy of the product are disclosed
International audienceRNA viruses are responsible for a large variety of animal infections. Equine A...
The Oklahoma Cooperative Extension Service periodically issues revisions to its publications. The mo...
We describe the development and preliminary characterization of a recombinant canarypox virus vector...
An inactivated viral vaccine for protecting horses against disease caused by equine rhinopneumonitis...
Equine arteritis virus EAV in the causative agent of the equine viral ateritis. The persistant infec...
Equine arteritis virus (EAV) is an enveloped plus-strand RNA virus of the family Arteriviridae (orde...
Disclosed is an in vivo equine disease model and a method of preparing the disease model for equine ...
The Oklahoma Cooperative Extension Service periodically issues revisions to its publications. The mo...
An isolated polynucleotide molecule includes a DNA sequence encoding an infectious RNA molecule enco...
Equine viral arteritis (EVA) is a serious viral disease of horses that can affect the respiratory sy...
An Escherichia coli-expressed recombinant protein (6hisG(L)ecto) comprising the entire ectodomain (a...
Equine viral arteritis (EVA) is an economically important viral disease of equids. Stallions can bec...
Equine viral arteritis (EVA) is an important disease that can result in severe economic losses for t...
The present invention relates, in general, to attenuated equine influenza viruses having an impaired...
AbstractAfrican horse sickness virus (AHSV) is an arthropod-borne pathogen that infects all species ...
International audienceRNA viruses are responsible for a large variety of animal infections. Equine A...
The Oklahoma Cooperative Extension Service periodically issues revisions to its publications. The mo...
We describe the development and preliminary characterization of a recombinant canarypox virus vector...
An inactivated viral vaccine for protecting horses against disease caused by equine rhinopneumonitis...
Equine arteritis virus EAV in the causative agent of the equine viral ateritis. The persistant infec...
Equine arteritis virus (EAV) is an enveloped plus-strand RNA virus of the family Arteriviridae (orde...
Disclosed is an in vivo equine disease model and a method of preparing the disease model for equine ...
The Oklahoma Cooperative Extension Service periodically issues revisions to its publications. The mo...
An isolated polynucleotide molecule includes a DNA sequence encoding an infectious RNA molecule enco...
Equine viral arteritis (EVA) is a serious viral disease of horses that can affect the respiratory sy...
An Escherichia coli-expressed recombinant protein (6hisG(L)ecto) comprising the entire ectodomain (a...
Equine viral arteritis (EVA) is an economically important viral disease of equids. Stallions can bec...
Equine viral arteritis (EVA) is an important disease that can result in severe economic losses for t...
The present invention relates, in general, to attenuated equine influenza viruses having an impaired...
AbstractAfrican horse sickness virus (AHSV) is an arthropod-borne pathogen that infects all species ...
International audienceRNA viruses are responsible for a large variety of animal infections. Equine A...
The Oklahoma Cooperative Extension Service periodically issues revisions to its publications. The mo...
We describe the development and preliminary characterization of a recombinant canarypox virus vector...